Mutations in one of the duplicated survival of motor neuron (SMN) genes lead to the progressive loss of motor neurons and subsequent development of spinal muscular atrophy (SMA), a common, and usually fatal, hereditary disease. Homozygous absence of the telomeric copy (SMN1) correlates with development of SMA because differential splicing of the centromeric copy (SMN2) leads to exon 7 skipping and predominantly produces a biologically inactive protein isoform. To increase exon 7 inclusion of SMN2, we have designed a series of vectors that express modified U7 snRNAs containing antisense sequences complementary to the 3V splice site of SMN exon 8. Over 20 anti-SMN U7 snRNAs were tested for their ability to promote exon 7 inclusion in the SMN2 gene. Transient expression of anti-SMN U7 snRNAs in HeLa cells modulated SMN2 splicing to~70% exon 7 inclusion in a sequence-specific and dose-dependent manner. Significantly, the administration of anti-SMN U7 snRNPs results in an increase in the concentration of SMN protein. These results suggest that modulation of SMN2 pre-mRNA splicing by modified U7 snRNAs provides a promising form of gene therapy for the treatment of SMA.
INTRODUCTION
Spinal muscular atrophy (SMA) is the second most common autosomal-recessive inherited disorder in humans and is the leading cause of hereditary infant mortality, with an overall incidence of 1 in 10,000 births and a carrier frequency of 1 in 50 [1] [2] [3] . It is characterized by the progressive degeneration of the motor neurons in the anterior horn cells of the spinal cord, which leads to progressive paralysis of the trunk and limbs. SMA is caused by deletions or mutations of the survival of motor neuron (SMN) gene, which has been mapped as an inverted repeat on chromosome 5 at position 5q13 [4] . Each SMN gene encompasses 27 kb including nine exons with the stop codon residing near the end of exon 7 [5] . Homozygous absence of the telomeric copy of the gene (SMN1) correlates with development of SMA [6, 7] . By contrast, alterations within the centromeric SMN gene (SMN2) do not produce any known phenotype [4] because SMN2 is only partially functional. Although sequence comparison of the two genes revealed that SMN1 and SMN2 differ by only 11 nucleotides and encode the identical protein [4, 8] , SMN1 primarily produces the full-length form of SMN, whereas differential splicing of the SMN2 pre-mRNA predominantly produces an isoform lacking exon 7 (SMND7). This differential splicing pattern in SMN2 has been attributed to a translationally silent, single-nucleotide C to U base difference located 6 nucleotides within exon 7 [8, 9] . This nucleotide change leads to inefficient inclusion of exon 7 in SMN2 by disrupting an exonic splicing enhancer (ESE) [10] , a cis-acting element that recruits the splicing machinery to exons [11, 12] or, alternatively, by increasing the activity of a splicing silencer [13] . The resulting protein SMND7 is not functionally equivalent to fulllength SMN and is unstable in vitro and in vivo [14] . Fulllength protein in SMA patients is therefore present only at low concentrations, thus giving rise to the SMA phenotype.
The SMN protein comprises 294 amino acids and has a molecular weight of 38 kDa. It is ubiquitously expressed and can be found in both the cytoplasm and the nucleus, where it is localized in punctate structures referred to as Gemini of coiled bodies [15] . However, SMN is expressed at approximately 100-fold higher levels in developing motor neurons [16] . Live imaging of tagged SMN in cultured motor neurons demonstrated that SMN displays rapid bidirectional movement within the outgrowths of motor neurons [17] , suggesting that SMN may be actively transported along the axon to the terminal endings of motor neurons. In addition, SMN oligomerizes and forms a stable complex with at least six additional proteins, Gemini 2 through Gemini 7 [18] [19] [20] . This SMN complex plays an essential role in the assembly and recycling of snRNPs, the major components of the spliceosome [21] [22] [23] . These data indicate that the SMN complex is an essential housekeeping factor involved in RNA metabolism. However, other reports demonstrated that SMN is also capable of interacting with the tumor suppressor proteins Bcl2 and p53, thus suggesting a potential role for SMN in the regulation of apoptosis [22, 24] .
Because all individuals with SMA have retained their SMN2 allele, therapy directed toward increasing SMN2 expression and/or SMN2 exon 7 inclusion could prove promising in lowering the clinical severity of SMA. Highthroughput drug screens have been set up to identify compounds that either increase the transcriptional level from the SMN2 locus or alter the splicing pattern of SMN2 in favor of exon 7 inclusion. As of today, a number of promising lead-compounds have been identified; however, they require further experimentation for potential application [25] [26] [27] [28] [29] . A second set of investigations has described the ability of a limited number of general splicing factors to influence exon 7 inclusion in SMN2 [30] [31] [32] . We and others have described antisense oligonucleotide approaches that make it possible to tilt the balance of the SMN2 splicing pathway specifically in favor of exon 7 inclusion [33] [34] [35] [36] .
To increase the longevity of the antisense oligonucleotide application, we have devised an antisense expression system that incorporates the anti-SMN region into the U7 small nuclear RNA. This approach has been used previously to modulate pre-mRNA splicing of thalassemic hglobin pre-mRNA [37] and has successfully corrected muscular dystrophy in a mouse model [38] . The U7 snRNP is a small nuclear particle containing an RNA region that base pairs with histone pre-mRNA [39, 40] . We have exchanged the natural anti-histone portion of the U7 snRNA with an anti-SMN2 portion, thus generating a modified U7 that is capable of interacting with the SMN2 pre-mRNA. Over 20 anti-SMN U7 snRNAs were tested for their ability to modulate SMN2 exon 7 inclusion. Cell culture experiments demonstrate that several of the modified anti-SMN U7 snRNPs are capable of restoring SMN2 exon 7 inclusion to levels similar to that of SMN1. Importantly, the administration of anti-SMN U7 snRNAs results in an increase in the concentration of SMN protein.
RESULTS

Design of Antisense Oligonucleotide Approach
Previous experiments demonstrated that competition between the 3V splice sites of exon 7 and exon 8 dictates the inclusion or exclusion of SMN2 exon 7 [33] . We have used this mechanistic information to pursue an antisense oligonucleotide approach that is designed to change the balance of 3V splice site usage in favor of exon 7 inclusion. For the initial test of principle, we used several chemically modified antisense oligonucleotides that were targeted to the 3V splice site of exon 8. It was our expectation that the antisense oligonucleotides directed to this splice site would block its recognition by the spliceosome. We speculated that this interference would shift the competition between the 3V splice sites of exon 7 and exon 8 in favor of exon 7 inclusion (Fig. 1A) . In fact, we have previously shown that the addition of chemically modified RNA antisense oligonucleotides to stable cell lines expressing the SMN1 or SMN2 minigene leads to a dosedependent change in exon 7 inclusion [33] .
To increase the efficacy and longevity of the antisense oligonucleotide approach and to prepare for testing in animal models, we have devised an antisense expression system that takes advantage of a naturally occurring antisense action, analogous to the approach taken to modulate splicing of the thalassemic h-globin pre-mRNA and muscular dystrophy dystrophin premRNA [37, 38] . U7 snRNP is a small nuclear particle consisting of an RNA component and several proteins. The 62-nt-long U7 RNA contains a region that base pairs with histone pre-mRNA to initiate histone premRNA 3V end processing. By changing the wild-type Sm-binding site of U7 snRNA into the consensus Sm- binding site (SmOpt), U7 snRNP can be converted into a highly expressed, but functionally inactive, particle [41, 42] . Because U7 SmOpt-derived snRNP particles do not recruit the histone 3V-end-processing machinery, they can be used to target other pre-mRNAs without triggering degradation [41, 42] . This approach has been proven successful to modulate pre-mRNA splicing in a number of applications [37, 38, 40, 43] . Using a similar approach, we have exchanged the natural anti-histone portion of the U7 SmOpt snRNA with a sequence complementary to the 3V splice site of SMN exon 8 (Fig. 1B) . Several modified anti-SMN U7 snRNAs were generated to evaluate whether embedding antisense sequences against the SMN pre-mRNA within U7 snRNA modulates SMN2 pre-mRNA splicing. The second goal was to determine whether the length of the antisense interaction with the intron 7/exon 8 junction or the specific target location significantly alters the efficiency of splicing modulation. The last objective was to determine whether the modulation in SMN premRNA splicing leads to increased levels of functional SMN protein.
U7 snRNAs Containing an Anti-SMN Region Modulate SMN2 Pre-mRNA Splicing For preliminary characterization, we cotransfected an initial set of anti-SMN U7 snRNAs into HeLa cells with the SMN2 minigene ( Fig. 2A) . As illustrated in Fig. 2B , the splicing analysis demonstrates that some anti-SMN U7 snRNPs significantly alter the splicing pattern of the SMN2 minigene in favor of exon 7 inclusion. However, not all anti-SMN U7 snRNAs are effective in achieving this goal (Fig. 2 , lanes 4-6). As a reference, the splicing patterns of SMN1 and SMN2 are shown in lanes 1 and 2, respectively. As expected, splicing of SMN1 leads primarily to inclusion of exon 7, while exon 7 is largely excluded from the final mRNA product in SMN2. Transfection of U7 SmOpt, the plasmid carrying the natural anti-histone sequence at the 5V end of the U7 snRNA, did not lead to any appreciable changes in the splicing pattern of SMN2 (Fig. 2, lane 3) . Furthermore, the high levels of exon 7 inclusion observed for SMN1 are not changed upon cotransfection of U7 snRNAs (data not shown). We conclude that the modulation of SMN2 pre-mRNA splicing exhibited by several anti-SMN U7 snRNAs (Fig. 2 , lanes 4-6) is due to their specific interactions with the SMN2 target site.
To ensure that the variations observed between the anti-SMN U7 snRNAs tested was not due to differences in expression levels, we determined the relative ratio of U7 snRNA expression to that of the housekeeping gene hypoxanthine phosphoribosyltransferase (HPRT). As demonstrated in Fig. 2C , all constructs tested exhibit essentially equal expression levels. Therefore, the lower efficiency of anti-SMN U7 snRNA B4 to modulate SMN2 pre-mRNA splicing is likely due to inefficient hybridization to the target site. Titration experiments demonstrate that maximal modulation efficiency for anti-SMN U7 snRNA F2 (~75%) is achieved with the transfection of 200 ng of the appropriate expression vector (Fig. 3 ). This effect is independent of the total amount of DNA transfected, as cotransfection of empty vector did not produce a significantly different modulation profile (Fig. 3 , compare lanes 1-6 with 7-11). We conclude that incorporating the SMN antisense sequence into the 5V end of U7 snRNAs does not compromise the modulation efficacy for most of the anti-SMN RNAs tested.
Optimization of the Anti-SMN U7 snRNA Methodology Our initial tests indicated that some anti-SMN U7 snRNAs were significantly more efficient in modulating SMN2 pre-mRNA splicing than others. In fact, anti-SMN U7 snRNA B2 altered the SMN2 splicing pattern from 30% exon 7 inclusion to approximately 73%, a sixfold change in the ratio of inclusion over exclusion. On the other hand, anti-SMN U7 snRNA B4 increased the levels of exon 7 inclusion only marginally, although the antisense sequence was designed to target the same general area. These observations suggest that the specific location targeted or the increased length of the antisense interaction significantly affected the modulation efficiency. This may be due to variations in hybridization and melting kinetics under physiological conditions. Although data acquisition has shown that larger regions of complementarity do not necessarily lead to greater efficacy, the theories of nearest neighbor contributions imply that longer sections of base complementarity should lead to increased duplex stability [44] . One important concern to consider when designing antisense RNAs is that the molecule maintains its single-stranded character for optimal hybridization kinetics. However, as the length of an RNA molecule is increased, the potential for forming relatively stable secondary structures increases exponentially [45] . Although we took care to minimize potential secondary structures of the SMN antisense region that encompasses the 5V end of the modified U7 snRNA, competing target structures could not be assessed a priori. To optimize the potential of the modulation approach, we designed 18 additional anti-SMN U7 snRNAs that exhibited reduced or extended base pairing with the SMN pre-mRNA target and differed slightly in location with respect to the intron 7/exon 8 junction (Fig. 4) . We tested all anti-SMN U7 snRNAs multiple times using the cell culture splicing assay. Fig. 4 summarizes the sequence context and splicing modulation efficiency of all anti-SMN U7 snRNAs investigated. In all three major classes of anti-SMN U7 snRNAs, antisense RNAs targeting the polypyrimidine tract (A1-D2), antisense RNAs targeting the intron/exon junction (D3-F4), and antisense RNAs targeting the 5V end of exon 8 (G1 and G2), at least one was observed to induce efficiently exon 7 inclusion to levels greater that 60%. Because minor sequence alterations in some of the anti-SMN U7 snRNAs resulted in significant changes in modulation efficiencies (Fig. 4 , compare for example F2 and F3), the potential for alternative secondary structure formation of the anti-SMN U7 snRNA administered is critical in determining efficacy.
The observed efficiency of modulating SMN2 premRNA splicing was correlated to thermodynamic and physical characteristics of the anti-SMN RNAs tested. A reasonable correlation was observed between the G/C content of the antisense sequence tested and the efficiency of induction of exon 7 inclusion (Fig. 5) . Fur -FIG. 4 . Summary of anti-SMN U7 snRNAs tested. The sequence of the SMN2 pre-mRNA is shown in the sense (5V-3V) direction. The sequence of the anti-SMN U7 snRNA are in the 3V-5V direction. Tm refers to the melting temperature of the duplex RNA formed between the anti-SMN U7 snRNA and the SMN2 pre-mRNA. The nucleotide length of the antisense sequence is indicated by nt. The G/C content for each anti-SMN U7 snRNA is indicated by %GC. The bar graph on the right illustrates the average efficiency of exon 7 inclusion for each of the anti-SMN U7 snRNAs tested. The error bars represent the standard deviation from at least nine independent experiments. The value of exon 7 inclusion for SMN1 is 97%.
thermore, the length of the most potent anti-SMN RNAs was between 18 and 22 nucleotides (Fig. 4) . However, we did not observe any correlation between the efficiency of exon 7 inclusion induction and the T m of the antisense RNA tested (data not shown). We conclude that optimal splicing modulation is achieved with antisense sequences around 20 F 2 nucleotides in length and with a G/C content close to 50%.
Coexpression of Two Different Antisense U7 snRNAs Does Not Increase the Efficacy of SMN2 Exon 7 Inclusion Previous work indicated that the coexpression of two different antisense U7 snRNAs to more than one target site leads to an increased efficacy in splice site modulation [46] . Although the goal of the antisense application in these cases was to suppress the recognition of a cryptic exon, we were interested in testing whether multiple targeting of the SMN2 pre-mRNA could result in further stimulation of exon 7 inclusion. In addition to the anti-SMN U7 snRNAs that target the intron 7/exon 8 junction, we also generated anti-SMN U7 snRNAs based on recent reports describing that antisense interference with an intronic silencer upstream of exon 7 or an interaction of peptide nucleic acids (PNAs) with regions of SMN2 exon 7 could increase the levels of exon 7 inclusion [34, 35] . As illustrated in Fig. 6 , we cotransfected the most potent antisense RNA, anti-SMN U7 snRNA G2, with anti-SMN U7 snRNAs targeting the intronic silencer (Ele1) or exon 7 (Ex7). The cotransfection of these anti-SMN U7 snRNAs did not lead to an increase in the levels of exon 7 inclusion (Fig. 6 , compare lane 2 with lanes 5 and 6). In contrast, the coexpression of these anti-SMN U7 snRNAs resulted in decreased exon 7 inclusion compared to G2 alone. Anti-SMN U7 snRNA Ex7 resulted in essentially complete exon 7 skipping, beyond the levels observed for SMN2 (Fig. 6, lane 3) . The fact that coexpression of G2 and Ex7 did not lead to any measurable exon 7 inclusion (Fig. 6, lane 5) demonstrates that the negative effects of anti-SMN U7 snRNA Ex7 dominate over the positive influence of anti-SMN U7 snRNA G2. Coexpression of anti-SMN U7 snRNAs G2 and B2, targeting nonoverlapping regions of the intron 7/ exon 8 junction, also did not lead to statistically significant increases in exon 7 inclusion over the effect each of the anti-SMN U7 snRNA individually (Fig. 6, lanes  8-10) . We conclude that the optimized anti-SMN U7 snRNA sequences already accomplish near-maximal splicing modulation of the SMN2 pre-mRNA.
Anti-SMN U7 snRNAs Increase SMN Protein Levels in Cell Culture
To address the question whether the administration of anti-SMN U7 snRNAs results in increased levels of SMN full-length protein, we performed quantitative Western analysis. Because the transfection efficiency of SMA patient fibroblast cell lines is low, we assessed the effects of anti-SMN U7 snRNAs in HeLa cells expressing endogenous SMN1 and SMN2. We generated HeLa cell lines that stably expressed anti-SMN U7 snRNAs F2, B2, G1, or G2. We then tested these cell lines for SMN expression. As illustrated in Fig. 7 , the presence of anti-SMN U7 snRNAs F2, B2, G1, or G2 led to an increase of up to 40% in the concentration of SMN (Fig. 7 , compare lanes 1-4 with lanes 5 and 6). With a greater than 96% confidence level (n = 8), this reproducible increase in SMN protein levels is statistically significant. The elevated levels of SMN protein are above the already existing expression from the SMN1 and SMN2 loci, both of which are present and activated in the cell lines used. Because U7 snRNA-directed splicing modulation does not further increase the levels of SMN1 full-length transcript, the measured increase in SMN protein levels of 40% reflects at least a threefold increase in the protein levels from the SMN2 locus, an increase from 20 to 60% of SMN2 pre-mRNAs that generate full-length protein. The change in SMN expression level is due to anti-SMN U7 snRNA F2, B2, G1, or G2 because transfection of an anti-histone U7 snRNA vector had no significant effect on SMN levels (Fig. 7, SmOpt, lane 5) . To control for loading errors, each lane was normalized to the expression levels of the housekeeping gene GAPDH (Fig. 7) . We conclude that the splicing modulation elicited by the administration of anti-SMN U7 snRNAs results in statistically significant and reproducible increases in SMN protein levels.
DISCUSSION
Initial experiments demonstrated that antisense oligonucleotides directed toward the intron 7/exon 8 junction led to a twofold increase in SMN2 exon 7 inclusion [33] . Because of these promising results, we have further improved the antisense technology to allow efficacy testing on endogenous levels of SMN and to develop prototype delivery vehicles that are suitable for animal testing. We have devised a scheme that allows for stable expression of antisense RNAs in cells. The antisense region that hybridizes to the SMN target was incorporated into the U7 snRNA, a heteronuclear RNA that, when assembled into the large RNA/protein particle, directs 3V-end processing of histone mRNAs in its natural context. However, when the U7 snRNA Sm binding site is changed to the consensus Sm binding site, the U7 snRNP particle is no longer functional in 3V-end processing. Using modified U7 snRNAs as vehicles to deliver an SMN antisense RNA, we were able to identify anti-SMN U7 snRNAs capable of altering the splicing pathway of SMN2 pre-mRNAs to include preferentially exon 7. These results indicate that SMN antisense RNA can be delivered in sufficient quantities and with sufficient stability to the vicinity of the cellular pre-mRNA processing machinery. The testing of multiple antisense sequences allowed us to determine the optimal antisense sequence length and to pinpoint the most ideal mRNA target location. Based on our analysis, the most efficient anti-SMN U7 snRNAs contained relatively short hybridization regions of~20 nucleotides with high G/C content. However, even some of the largest antisense sequences tested were fairly efficient in modulating exon 7 inclusion (Fig. 4 , anti-SMN U7 snRNA D5). Efficient anti-SMN U7 snRNAs were identified that target the polypyrimidine tract, the intron/exon junction, or the 5V end of exon 8. These observations suggest that masking of the U2AF binding site, blocking the intron/exon junction, or masking of potential ESEs located within the 5V end of exon 8 can trigger efficient splicing interference.
Although extreme care was taken to design antisense sequences with limited abilities to form secondary structures, minor sequence changes within the antisense region of the modified U7 snRNA could result in a significant reduction in splicing modulation. For example, the addition of one nucleotide at the 3V end resulted in a loss of anti-SMN U7 snRNA activity (Fig. 4 , compare anti-SMN U7 snRNAs D1 and D2). Similarly, changing nucleotides within the same anti-SMN U7 snRNA to allow wobble base pair interaction with the target site resulted in a significant drop in anti-SMN U7 snRNA activity (Fig. 4 , compare anti-SMN U7 snRNAs F2 and F3). These results suggest that in addition to antisense sequence length and G/C content, competing secondary structures of the anti-SMN U7 snRNAs are crucial in dictating the efficacy of SMN splicing modulation. Importantly, we were able to identify anti-SMN U7 snRNAs capable of altering the splicing pathway of SMN2 pre-mRNAs to include preferentially exon 7, thus increasing the levels of functional SMN protein.
The benefits of embedding antisense sequences within the U7 snRNA are multifold. As U7 snRNAs are nuclear, the design ensures that the antisense agent is enriched within the organelle that executes pre-mRNA splicing. In addition, when transcribed in the target cell, the modified U7 snRNA is capped at the 5V end and bound by endogenous proteins analogous to endogenous U7 snRNA, thus increasing the half-life of the RNA. Unlike the administration of chemically modified antisense RNAs or PNAs, the anti-SMN U7 snRNAs are generated continuously within the cell. This advantage is illustrated strikingly by the generation of stable cell lines expressing anti-SMN U7 snRNAs. Efficient modulation of exon 7 inclusion is persistent over many cell divisions, as long as the expression cassette is retained within the cell. Finally, the modified U7 methodology allows incorporation into viral vector systems required for gene therapy approaches. These benefits are further exemplified by the recent finding that administration of U7 snRNAs with complementarity to dystrophin in an AAV vector leads to exon skipping and the rescue of Duchenne muscular dystrophic mice [38] . Results from this study suggest that the SMA phenotype may also be corrected using this technology.
Previous studies demonstrated that the coexpression of antisense sequences to more than one target site could synergize in modulating pre-mRNA splicing of h-globin [46] . Two approaches were used in this study. First, two different U7 snRNAs were cotransfected, each of which interacted with a different region of the pre-mRNA. In the second approach, two different antisense regions were embedded within the same U7 snRNA, thus looping out the targeted exon [46] . Both approaches could generate significantly higher frequencies of exon skipping. However, in the case of SMA, exon inclusion is the desired outcome of the pre-mRNA splicing modulation, thus eliminating the double targeting approach as it loops out and skips the affected exon. A recent report identified an intronic splicing suppressor element that lowers exon 7 definition [34] . Although this repressor is common to both SMN1 and SMN2, its activity is amplified in the SMN2 context in which the C to U transition in exon 7 either destroyed the activities of an exonic splicing enhancer [10] or, alternatively, generated a splicing silencer [13] . To test whether this element could augment the splicing modulation observed with anti-SMN U7 snRNAs directed toward the 3V splice site of exon 8, we coexpressed anti-SMN U7 snRNAs directed toward the 3V splice site of exon 8 and the repressor element located within intron 6. However, our attempts to stimulate exon 7 inclusion further by double targeting the SMN2 premRNA did not lead to significant improvements of the modulation efficiency. Contrary to our expectations, we observed reduced efficiencies of exon 7 inclusion. These observations suggest that the optimized anti-SMN U7 snRNAs targeting the 3V splice site of exon 8 already tilt the balance of exon 7 inclusion to the maximum level achievable by U7 snRNA antisense interference. Although this maximum (~70% exon 7 inclusion) is below the exon 7 inclusion probability of the SMN1 gene (95%), the modulation of splicing could provide significant protection against SMA. This hypothesis is furthermore supported by our finding that application of anti-SMN U7 snRNAs not only modulates the splicing pattern of the SMN2 gene but also leads to a threefold increase in SMN full-length protein from the SMN2 locus.
The clinical severity of the disease has been correlated with the copy number of the SMN2 gene [47] . The majority of SMA type I, the most severe form of SMA, is characterized by two copies of SMN2 and loss of functional SMN1. The least severe clinical type, SMA type III, is characterized by three or four copies of the SMN2 gene with loss of functional SMN1. In theory, an up-regulation of SMN2 exon 7 inclusion from the typical 20% inclusion to 70% inclusion should be sufficient to increase SMN protein levels in type I patients to type III levels or those of type III patients to levels of normal individuals.
The RNA antisense-mediated approach to alter premRNA splicing patterns relies on RNA/RNA interactions that interfere with the recognition of splice site signals within the target pre-mRNA. The goal of the antisense approach is not to trigger the destruction of the target RNA, but rather to alter its processing. Kole, Schqmperli, and co-workers have demonstrated that the incorporation of antisense sequences into small nuclear RNAs could provide stability and prolonged expression of the antisense agent [37] . Here, we have demonstrated that the modified U7 snRNP approach can also be applied to manipulate the splicing pattern of the SMN2 pre-mRNA. The shuttle system ensures the delivery of antisense RNA to the nucleus and thus provides increased stability by protecting the antisense RNA from degradation. These encouraging observations suggest that the modified U7 snRNA approach holds great promise for future work that intends to put the methodology to the test in SMA animal models. Therefore, we will concentrate on integrating the SMN2 modified U7 snRNAs into a viral gene delivery system that holds the promise of being of significant potential for future studies in living organisms.
MATERIALS AND METHODS
DNA. U7 SmOpt (courtesy of Daniel Schqmperli) expresses the mouse U7 snRNA gene with an optimized Sm binding sequence [41] . The 5V end of the U7 snRNA contains the region complementary to the histone premRNA 3V-end processing site. This 18-nucleotide sequence was replaced with sequences complementary to the intron 7/exon 8 junction of the SMN pre-mRNA. Each insert was generated by PCR and inserted by exonuclease III cloning [48] into the StuI and HpaI sites of U7 SmOpt. All clones were verified by sequence analysis. Sequence information about the PCR primers used is available upon request. SMN1 and SMN2 minigene constructs contain exon 6 through exon 8, including intervening sequences that have been inserted into the pCI mammalian expression vector (courtesy of Elliot Androphy [9] ).
Design of antisense oligonucleotides. All modified U7 snRNAs target the intron 7/exon 8 junction site to interfere with exon 8 recognition by the splicing machinery. It is anticipated that a reduction in the kinetics of exon 8 recognition (by antisense oligonucleotide interference) will result in increased levels of exon 6 to exon 7 splicing. Antisense sequences were considered within the range of 36 nucleotides upstream and 34 nucleotides downstream of the intron 7/exon 8 junction. This area was systematically screened for optimal antisense RNAs of 15 to 30 nucleotides in length. RNA secondary structure prediction programs were used to evaluate the potential of each antisense sequence to form strong intramolecular structures. Wobble base pair interactions were allowed if their presence resulted in preventing antisense RNAs from adopting secondary structures. To maintain its natural context, the 5V ends of all antisense modified U7 snRNAs contain a CAA. Potential antisense RNAs were scored based on the above criteria. The 21 most promising RNAs were cloned and tested.
Cell culture and transfections. HeLa cells were grown in MEM supplemented with 10% (vol/vol) FBS and 2 mM glutamine and plated at 1-3 Â 10 5 cells/well 20-24 h before transfection in 24-well plates. Typically, 0.5
Ag of the SMN2 minigene and 0.5 Ag of anti-SMN U7 snRNA were cotransfected using LipoFectamine 2000 and incubated for 24 h. Total RNA was extracted and then isolated using the TRIzol reagent according to the manufacturerTs protocols. Reverse transcription of total RNA was performed with oligo(dT) and M-MLV for at least 1 h at 378C. PCR analysis was then performed to identify spliced products. PCR was done for 30 cycles in the presence of 0.2 mM dNTP. Each cycle consisted of a 30-s denaturation step at 948C, a 40-s annealing step at 528C, and a 50-s extension step at 728C. Primers used to amplify spliced products were pCIfor (5V-GCTAACGCAGTCAGTGCTTC-3V) and Ex8-Rev (5V-GGGGA-TATTTTGAAGAAATGAGG-3V). Reaction products were fractionated on a 2% agarose gel. The resulting bands were visualized and quantitated using a Gel-Doc imager (Bio-Rad). The exon 7 inclusion efficiency was calculated by computing the pixel count of exon 7 included over the sum of the pixel counts of exon 7 included and excluded. Transfection experiments were repeated at least five times. The expression of each anti-SMN U7 snRNA was determined relative to the expression of the housekeeping gene HPRT. Specific amplification of the transfected anti-SMN U7 snRNA over endogenous U7 snRNA was accomplished by using clone-specific primers. Sequence information about the PCR primers used is available upon request.
U7 snRNA stable cell cultures and Western blot analysis. To allow the expression of transgenes and the selection of the resistance gene from one plasmid, the coding sequences for U7 snRNAs B2, F2, G1, G2, and SmOpt were cloned into the pCI-neo vector (Promega). The CMV promoter sequence was cut out of pCI-neo to prevent interference with the U7 promoter. These constructs were stably transfected into HeLa cells using LipoFectamine2000 (Invitrogen). Permanently transfected cells were selected in a medium containing 400 Ag/ml G418. To determine the expression of SMN in cell lines stably transfected with anti-SMN U7 snRNAs, quantitative Western analysis was performed according to standard protocols. All SMN expression patterns were normalized to the expression of the housekeeping gene GAPDH. These values were compared to SMN levels in untransfected cells and cells stably expressing the anti-histone U7 snRNA (SmOpt). SMN was detected using a BD Biosciences monoclonal SMN antibody, GAPDH with a Chemicon monoclonal antibody. For the quantitation of protein levels a Bio-Rad chemiluminescence reader (Fluor-S) was used.
